BioNTech Results Presentation Deck

SITC 2021 - BNT311 Phase 1/2: Pharmacodynamic Effects Consistent with Proposed Mechanism of Action in Patients with NSCLC who Progressed on PD-L1 Therapy Peripheral and tumoral immune activity in expansion cohort of patients with PD-L1-R/R NSCLC 27 ● Positive pharmacodynamics responses Induction of cytokines (IFN-y & CXCL9/10) Expansion of CD8+ effector memory T cells & activated NK cells 5 patients with confirmed partial response Greater induction of IFN-y, CXCL9/10 and activated NK cells in responders vs non-responders 6 Relationship between disease control and PD-L1 expression, as well as time from last prior anti-PD-1 therapy Higher disease control rates in patients with prior anti-PD-1 therapy within 8 months from first dose of study drug Patients with tumor reduction mainly PD-L1+ tumors Phase 2 trial of BNT311 as monotherapy and in combination with pem brolizumab in R/R metastatic NSCLC expected to start in Q4 2021 CXCL, chemokine (C-X-C motif) ligand; IFN, interferon; NK, natural killer; NSCLC, non-small cell lung cancer; R/R, relapsed/refractory BIONTECH

View entire presentation